Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B

Kaitao Zhao1,2, Shuhui Liu1,2, Yingshan Chen1,2, Yongxuan Yao1,2, Ming Zhou3, Yifei Yuan1,2, Yun Wang1, Rongjuan Pei1, Jizheng Chen1, Xue Hu1, Yuan Zhou1, He Zhao1, Mengji Lu6, Chunchen Wu1 and Xinwen Chen1,2

Abstract
Sodium taurocholate cotransporting polypeptide (NTCP) is a functional receptor for hepatitis B virus (HBV) entry. However, little is known regarding whether NTCP is involved in regulating the postentry steps of the HBV life cycle. Here, we found that NTCP expression upregulated HBV transcription at the postentry step and that the NTCP-targeting entry inhibitor Myrcludex B (MyrB) effectively suppressed HBV transcription both in an HBV in vitro infection system and in mice hydrodynamically injected with an HBV expression plasmid. Mechanistically, NTCP upregulated HBV transcription via farnesoid X receptor α (FXRα)-mediated activation of the HBV EN2/core promoter at the postentry step in a manner that was dependent on the bile acid (BA)-transport function of NTCP, which was blocked by MyrB. Our findings uncover a novel role for NTCP in the HBV life cycle and provide a reference for the use of novel NTCP-targeting entry inhibitors to suppress HBV infection and replication.

Introduction
With ~240 million chronically infected individuals worldwide, Hepatitis B virus (HBV) infection remains a major global health burden1. Persistent HBV infection leads to liver cirrhosis and hepatocellular carcinoma2. Although currently approved clinical treatments for HBV infection based on interferon alpha (IFN-α) or nucleos(t)ide analogs provide reasonable control of viral production in chronic infection, HBV clearance and subsequent seroconversion only occur in a minority of patients. Overall, HBV eradication and/or resolution of infection remains a challenge3. Therefore, the development of new anti-HBV agents targeting other steps of the HBV life cycle is urgently needed.

As sodium taurocholate cotransporting polypeptide (NTCP) has been identified as the functional receptor for HBV entry4, entry inhibitors targeting NTCP offer a promising novel therapeutic option5. One such entry inhibitor is Myrcludex B (MyrB), a myristoylated synthetic lipopeptide comprising 47 amino acids derived from the preS1 domain of the HBV large surface protein. MyrB can efficiently block de novo HBV and HDV infection both in vitro6 and in vivo7. Moreover, MyrB administration may also prevent intrahepatic viral spread in HBV-infected uPA/SCID mice8. MyrB was recently confirmed to be well tolerated in healthy volunteers9, with antiviral efficacy against HBV and HDV infection10.

In addition to being the receptor for HBV and HDV, NTCP is an important bile salt transporter. NTCP is...
replication. Therapeutic strategies to interfere with HBV infection and entry-suppressing effect, and this report will provide a role of NTCP, independent of its receptor function, in the HBV life cycle. Moreover, the upregulation of HBV transcription by NTCP was further assessed, demonstrating that replication of the HBV A-C genotypes was enhanced by the NTCP, though at different efficiencies (Fig. S1).

Previous studies have shown that although it retains the function of BA transport, hNTCP with amino acids (aa) 157–165 replaced by the corresponding monkey sequence (mkNTCP) does not support HBV entry. To rule out the possibility that newly produced HBV virions from pSM2-transfected cells infect Huh7-NTCP cells, we introduced a mutated protein, NTCP/mk, consisting of hNTCP with aa 157–165 having been replaced by the mkNTCP sequence. We found that the NTCP/mk was still able to increase the HBV RNA, DNA, and HBsAg levels, albeit at a reduced rate compared with that of the wild-type NTCP (Fig. S2).

Furthermore, we investigated whether the NTCP can upregulate HBV replication in a dose-dependent manner. A gradient concentration of pcDNA3.1-NTCP plasmids was cotransfected with the HBV replication-competent plasmid pSM2. Accordingly, dose-dependent increases in intracellular HBV RNA, DNA, core protein, and capsid were observed (Fig. S3a); dose-dependent decreases were also observed for the HBV DNA levels contained in the secreted enveloped virions and naked nucleocapsids, as well as in the secreted HBsAg (Fig. S3b, c).

Taken together, these results indicate that NTCP expression significantly enhanced HBV replication at the postentry step.

**Entry inhibitor Myrcludex B (MyrB) abolished the NTCP-mediated upregulation of HBV replication**

The NTCP-targeting entry inhibitor MyrB is a promising novel candidate against HBV and is currently in clinical development. Therefore, the impact of MyrB on NTCP-mediated upregulation of HBV replication was further investigated. First, the potential cytotoxicity of MyrB treatment on hepatoma cells was ruled out (Fig. S4a). As shown in Fig. 2a, MyrB reduced the NTCP-dependent increases in HBV RNA, DNA, core protein, and capsid levels in a dose-dependent manner, with a marked effect at 2 μM. Correspondingly, MyrB treatment also caused dose-dependent decreases in secreted HBV DNA (Fig. 2b) and HBsAg (Fig. 2c). Consistent results were obtained in experiments using HepG2.2.15 cells with
Fig. 1 (See legend on next page.)
stable NTCP expression (Fig. 2d–f) and HBV A–C genotypes (Fig. S1). These findings indicate that MyrB can abolish the NTCP-mediated upregulation of HBV replication.

**MyrB inhibited HBV replication at the postentry step in an HBV in vitro infection system**

As hepatoma cell lines with stable NTCP expression have been used for in vitro HBV infection14,17, we further investigated the effect of MyrB on HBV at the postentry step using the same in vitro infection system (Fig. 3a), and MyrB was added to the culture medium at 16 h after HBV infection and sustained for 9 days18. As shown in Fig. 3b, MyrB significantly reduced the levels of the HBsAg in cell culture supernatants by 29%, 53%, and 50% at 5, 7, and 9 dpi, respectively. HBeAg levels were also reduced by 22% and 17% at 7 and 9 dpi, respectively. In addition, at 9 dpi, both extracellular and intracellular HBV DNA, pgRNA, and total RNA levels were decreased by 49%, 48%, 43%, and 55%, respectively (Fig. 3c, d). According to immunofluorescence and western blot assays, the core protein expression level significantly decreased after the MyrB treatment (Fig. 3e). Thus, MyrB inhibited the HBV replication at the postentry step in an HBV in vitro infection system.

**MyrB inhibited HBV replication by targeting mouse NTCP in vivo**

MyrB can bind to mouse NTCP and block its BA-transporter function15; therefore, the antiviral effect of MyrB on HBV was further assessed in mice. Because HBV infection is not supported in mice20, we hydrodynamically injected the HBV replication-competent plasmid pSM2 into C57BL/6 mice. Immunohistochemistry (IHC) staining showed obvious suppression of the level of HBV core protein by the MyrB treatment (Fig. 4a). The levels of HBsAg, HBeAg (Fig. 4b) and HBV DNA (Fig. 4c) in the mouse sera were also significantly decreased by MyrB administration. Consistent results were obtained for HBV RNA (Fig. 4d, e) and DNA (Fig. 4f) in the liver. These results confirmed that the MyrB treatment inhibited HBV replication by targeting mouse NTCP in vivo.

**MyrB abolished NTCP-mediated upregulation of HBV replication by inhibiting NTCP-mediated BA uptake**

In addition to blocking HBV entry, MyrB can bind to NTCP to inhibit BA uptake mediated by NTCP, as shown by previous reports15,17 and our data (Fig. S5a and b). Thus, we suspect that MyrB may counteract the NTCP-mediated upregulation of HBV replication by inhibiting NTCP-mediated BA uptake. We employed the mutated variant NTCP/mk to test this hypothesis. NTCP/mk retained the function of BA uptake (Fig. S5c), which was not blocked by MyrB due to the inability of the NTCP/mk to bind to the MyrB (Fig. S5a)15. In this setting, the upregulation of HBV replication by NTCP/mk was not affected by MyrB treatment (Fig. 5). These results demonstrated that MyrB abolished the NTCP-mediated upregulation of HBV replication by inhibiting the BA uptake.

**NTCP-mediated BA uptake specifically enhanced the activity of the HBV EN2/core promoter through FxRα**

According to the above results, we can infer that the observed upregulation of HBV by NTCP mainly depended on its BA-transporter function. Considering that FxRα is one of the most important sensing receptors for BAS21–23 and participates in HBV transcription via the regulation of HBV core promoter activity13, we hypothesized that FxRα may be involved in the mechanism by which the NTCP upregulates HBV replication. Therefore, we first analyzed the impact of NTCP expression on a series of HBV promoters and found only the activity of the HBV EN2/core promoter to be significantly augmented (Fig. 6a). To confirm the role of FxRα in this process, the two binding sites of FxRα in the EN2/core promoter were mutated13. As a result, the activity of the mutant EN2/core promoter was no longer enhanced by the NTCP expression (Fig. 6b), with the essential role of FxRα being inferred. Furthermore, we utilized guggulsterone Z (GGS), an FxRα antagonist, which had no toxic effect on cells (Fig. 5b). The GGS treatment completely offset the impact of the NTCP expression on the EN2/core promoter, as shown in Fig. 6c. In addition, when the expression of the FxRα was knocked down, the effect of the NTCP on the EN2/core promoter was obviously impaired (Fig. 6d). These results...
Fig. 2 MyrB inhibits HBV replication in NTCP-expressing cells. Huh7 cells transfected with the indicated plasmids, HepG2.2.15 cells and HepG2.2.15-NTCP cells were treated with MyrB at the indicated concentrations. a, d HBV transcription and replication intermediates were detected by northern blotting and Southern blotting, respectively (top panel). Expression of NTCP and core proteins and capsid formation in cells were analyzed by western blotting (bottom panel). b, e HBV DNA in enveloped virions and naked nucleocapsids in culture supernatants were detected by real-time PCR (n ≥ 3). c, f HBsAg and HBeAg in the culture supernatants were detected by ELISA (n ≥ 4). A two-tailed t-test was used to determine differences in the multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001
indicate that NTCP specifically enhanced HBV EN2/core promoter activity through FxRα.

To identify the role of NTCP-mediated BA uptake in this process, MyrB was applied as an uptake inhibitor, and the observed upregulation of EN2/core promoter activity by NTCP expression was counteracted by the MyrB treatment in a dose-dependent manner (Fig. 6e). Due to the NTCP/mk’s inability to bind to the MyrB, the upregulation of EN2/core promoter activity by the NTCP/mk was not affected by the MyrB treatment (Fig. 6f). Additionally, we found that glycocholic acid (GCA) enhanced the augmentation effect of the NTCP on EN2/core promoter activity in a dose-dependent manner (Fig. 6g), indicating that the NTCP specifically enhanced the activity of the HBV EN2/core promoter through FxRα, which was activated by NTCP-transported BAs.

Even BAs could directly activate FxRα and enhance HBV core promoter activity. NTCP expression also specifically increased the FxRα mRNA (0.75-fold) (Fig. 6h) and protein levels (0.7-fold) (Fig. 6i) among known transcription factors for the HBV core promoter13,24,25.

**NTCP upregulated HBV transcription specifically through FxRα-mediated activation of the HBV EN2/core promoter**

We further employed GGS to assess whether NTCP specifically upregulates HBV transcription through FxRα in the Huh7-NTCP cells and in the primary human hepatocytes (PHHs) infected with HBV (Fig. 7a, f). GGS significantly reduced the levels of secreted HBsAg and HBeAg in both cells (Fig. 7b, g). Consistently, levels of both extracellular and intracellular HBV DNA, pgRNA and total RNA were also markedly decreased (Fig. 7c, d, h, i). Immunofluorescence (Fig. 7e, j) and western blotting (Fig. 7e) assays showed that the expression levels of the core proteins were significantly decreased after GGS treatment. Consistent results were also obtained in experiments involving Huh7 cells transfected with the HBV expression plasmid in (Fig. S6a-c) and HepG2.2.15 cells with stable HBV expression...
To validate the specific role of FxRα in NTCP-dependent upregulation of HBV transcription, FxRα binding site mutations were introduced into the HBV genome (Fig. 8). As expected, the NTCP expression cannot increase the HBV RNA, DNA and protein levels any more (Fig. 8). Therefore, the NTCP specifically upregulated the HBV transcription by activating the HBV EN2/core promoter through the action of the FxRα.
Discussion

NTCP has been shown to act as a functional receptor and major host-specific restriction factor for HBV infection. As a peptidic NTCP inhibitor, MyrB is widely assumed to be an HBV entry inhibitor, and its efficacy in targeting HBV infection has been evaluated clinically. In the present study, NTCP was found to upregulate the HBV replication independent of its receptor function but does so depending on its BA-transporter function. We found that NTCP preferentially transported glycine- and taurine-conjugated BAs such as GCA-activated FXR to upregulate HBV transcription, and MyrB abolished this NTCP-mediated upregulation of HBV replication both in vitro and in vivo. To our knowledge, this study is the first to demonstrate the role of NTCP in HBV replication at the postentry step and the potential antiviral activity of MyrB as an HBV replication inhibitor.

The physiological function of NTCP, as a key BA transporter, is to transport BAs from the portal blood into hepatocytes, a process that is important for maintaining BA homeostasis. The amino acids of NTCP that have been reported as critical for efficient viral infection also contribute to BA binding. Nonetheless, different from the sodium concentration dependency for transporting substrates, NTCP binding to HBV pre-S1 is largely independent of the sodium gradient between the extracellular and intracellular compartments. Furthermore, both monkey and mouse NTCP are capable of transporting BAs, even though they do not support HBV and HDV infection. According to our results, mutated NTCP/mk, with the capacity to transport BAs, did not function as an HBV receptor (Fig. S5). Thus, NTCP’s physiological function of transporting BAs may not be required for its role in mediating viral entry. Here, we show that NTCP upregulated HBV replication at the postentry step and that this depended on the continued functioning of NTCP as the means of transport for the BAs. Therefore, NTCP is involved in HBV entry as well as transcription.

BAs act as natural ligands of FXR and thus directly activate FXR. Furthermore, they enhance HBV core promoter activity. Thus, NTCP-transported BAs could directly activate the FXR, and they upregulated the HBV transcription. In addition to FXR, BAs can activate a range of other nuclear receptors (NRs) and thus regulate the expression of genes involved in many biological processes. Overexpression of NTCP increased the transcription FXR but only slightly. Thus, the significant effect of NTCP on HBV transcription mainly resulted from the direct activation of FXR by NTCP-transported BAs. SIRT1 regulated the FXR activity, and the effect of FXR on the HBV transcription was substantially enhanced by SIRT1. Whether NTCP might affect the FXR activation by SIRT1 is under investigation.
Fig. 6 NTCP specifically improves activity of the HBV EN2/core promoter through FxRα. Huh7 cells transfected with the indicated plasmids were harvested. a Firefly luciferase activity was determined at 48 hpt. b Partial sequence of the construct pGL3-EN2/core (FxRα/WT) and the mutant construct of pGL3-EN2/core-FxRα/EmCm showed the FxRα binding sites and mutations introduced in EN2 (nts 1682 to 1694) and core (nts 1764 to 1776) promoter regions (top panel). Huh7 cells transfected with the indicated plasmids were harvested to determine firefly luciferase activity at 48 hpt (bottom panel). c Chemical structure of the FxRα antagonist GGS (top panel). Huh7 cells transfected with the indicated plasmids were treated with or without 10 µM GGS and then harvested to determine firefly luciferase activity at 48 hpt (bottom panel). d Huh7 cells transfected with the indicated plasmids and siRNAs were harvested to determine firefly luciferase activity at 48 hpt (top panel). The expression of FxRα was detected by western blotting (bottom panel). e–g Huh7 cells transfected with the indicated plasmids were treated with MyrB or GCA and then harvested to determine firefly luciferase activity at 48 hpt. h Total RNAs were extracted, and the mRNA levels of several transcription factors were detected by qRT-PCR. mRNA levels were normalized to β-actin mRNA. i The expression of FxRα was analyzed by western blotting. A two-tailed t-test was used to determine differences in multiple comparisons (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ns: P > 0.05.
Fig. 7 (See legend on next page.)
Although previous reports have shown that chenodeoxycholic acid (CDCA) activates the HBV EN2/core promoter through FXRα in the Huh7 cells13, the effect appears to be independent of NTCP expression because the expression level of NTCP is very low in the Huh7 cells4 and CDCA uptake occurs primarily through simple diffusion31. We also found that CDCA increased the activity of the HBV EN2/core promoter in a dose-dependent manner regardless of whether the NTCP was expressed (Fig. S7a). Compared with unconjugated BAs such as CDCA, NTCP prefers to transport glycine- and taurine-conjugated BAs such as GCA32. In agreement with this report, we found that GCA enhanced EN2/core promoter activity, which was dependent on the NTCP expression (Fig. 6g). Hence, our data showed that GCA was transported by NTCP-activated FXRα and thus upregulated HBV transcription, which is quite different from the previous reports that had suggested unconjugated BAs such as CDCA activated FXRα and thus upregulated HBV replication21. Overall, it would be interesting to identify whether other conjugated BAs preferentially transported by NTCP also play a similar role during this process.

Because of NTCP’s key role in mediating HBV entry, the peptidic NTCP inhibitor MyrB has been recognized as an effective HBV entry inhibitor6,8, and its efficacy in targeting HBV infection has been evaluated clinically9,10. Notably, MyrB can also inhibit the BA transport mediated by NTCP15. Thus, although mouse NTCP does not support HBV entry19, MyrB still suppresses HBV replication...
in an HBV hydrodynamic injection mouse model (Fig. 4). We also found that although HBV replication was not affected in the first 3 days post infection, impairment began on day 5 post infection (Fig. 3b), indicating that only sustained MyrB treatment efficiently inhibited HBV replication. Accordingly, the effect of MyrB on viral replication cannot be detected when the cells are incubated with MyrB for only 16 h. Interestingly, recent studies have revealed that MyrB treatment significantly affects plasma BA levels in healthy volunteers, further hinting at the possibility of MyrB as an HBV replication inhibitor because the inhibition of BA uptake may help to suppress HBV replication, as shown in our study. In addition, because MyrB inhibits HBV replication by inhibiting NTCP-mediated BA transport, the antiviral efficacy of MyrB was dependent on the expression of NTCP (Fig. 2). Considering that NTCP expression dropped sharply in ex vivo-cultured PHHs (Fig. S8), the inhibitory effect of MyrB on HBV replication in PHHs was not observed (Fig. S8).

In conclusion, our study demonstrated that in addition to the entry step, NTCP is able to upregulate HBV replication independent of its receptor function, which can be offset by the specific NTCP-targeting entry inhibitor MyrB. These results suggest that the drug MyrB could potentially target HBV, and HDV entry may also possess antiviral activity toward intracellular HBV. These findings further broaden our knowledge regarding the role of NTCP in the HBV life cycle. Additionally, our results provide a reference for developing anti-HBV agents targeting NTCP and for comprehensively assessing the therapeutic effect of such specific NTCP inhibitors as MyrB.

Materials and methods
Cell culture and HBV infection
Huh7, Huh7-NTCP, and HepG2.2.15 cells were cultured as described previously. The HepG2.2.15-NTCP cell line stably expressing human NTCP (hNTCP) was generated by infecting HepG2.2.15 with recombinant lentivirus, as described previously. Primary human hepatocytes (PHHs) were provided by XenoTech (Kansas City, KS, USA) and cultured according to the manufacturer’s instructions. These cells were all confirmed to be mycoplasma-negative.

For HBV infection, $5 \times 10^5$ Huh7-NTCP cells were seeded in 12-well plates, or $1.5 \times 10^5$ PHHs were seeded in 48-well plates for 4 h. Next, the medium was changed with fresh culture medium with 2% DMSO and left for another 24 h. The cells were infected by inoculation with ~500 genome equivalents (ge) per cell of HBV in the presence of 4% PEG8000. After 16 h, the infection inoculum was removed, and the cells were washed three times with phosphate-buffered saline (PBS) and maintained subsequently in culture medium with 2% DMSO and 2 μM MyrB or 10 μM GGS. The medium was changed every 2 days.

HBV capsid extraction and native agarose gel electrophoresis
The HBV capsids in the cells were extracted and detected as described previously. Briefly, the cells were harvested with 200 μl-specific lysis buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 50 mM NaCl, 8% sucrose, and 0.25% NP-40) and incubated on ice for 10 min. The samples were centrifuged for 10 min at 13,000 rpm and 4 °C. The supernatants were incubated with 6μM MgCl$_2$, 40μg DNaseI and 300μg RNase for 20 min at 37 °C, followed by centrifugation for 10 min at 13,000 rpm and 4 °C. The supernatants were resolved by 1.6% native agarose gel electrophoresis for 2.5 h (volt = 45 V) at 4°C. A nitrocellulose membrane was used for capsid transfer via adsorption overnight. The anti-Core (DAKO) antibody was used for capsid detection.

Southern blotting and northern blotting
Total cellular RNA was extracted using TRIzol reagent (Ambion, Carlsbad CA, USA) according to the manufacturer’s instructions and subjected to northern blotting as described previously. Encapsidated HBV replication intermediates in the cells were extracted and subjected to Southern blotting as described previously.

Real-time PCR
One-step quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to analyze specific mRNAs. HBV DNA in cell culture supernatants was extracted and detected using real-time PCR. The primers used are listed in Supplementary Table 1.

Hydrodynamic injection in mice
Male C57BL/6 (H-2b) mice (5–6 weeks of age) were used, and the hydrodynamic-based HBV mouse model was employed as described previously. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals according to the regulations in the People’s Republic of China. All animal experiments were approved by the Institutional Animal Ethical Committee of WIV, CAS (Serial number: WIVA02201701). Mice were kept under specific-pathogen-free (SPF) conditions in the Central Animal Laboratory of the Wuhan Institute of Virology, Chinese Academy of Sciences (WIV, CAS. License number: SYXK2014-0034). All animals in these studies were maintained under the following conditions: 5–6 animals per cage (Sealsafe™, Tecniplast, Varese, Italy), controlled temperature: 22 ± 1 °C, controlled relative humidity: 55 ± 15%, air conditioning: air filtered.
through a HEPA filter, 12 h-light/dark cycle (0800–2000 h light), diet: SPF rat maintenance feed (Keeoxieli, Beijing, China). The mice were anesthetized with isoflurane and then euthanized by cervical dislocation at the experimental endpoint.

Male mice (8 mice each group), randomly divided into the control group and treatment groups, were hydrodynamically injected with 14 μg pSM2 via the tail vein within 5–7s. MyRB and control peptide were reconstituted in water and diluted with PBS to reach a final concentration of 50 μg/ml. The 5 μg dose was administered twice daily (0900 and 2100) by subcutaneous injection, with each injection containing 2.5 μg peptide. Mice were euthanized by cervical dislocation at 4 days posthydrodynamical injection (dphi). The levels of HBeAg, HBsAg and HBV DNA in the serum were detected by ELISA daily. For analysis of the serum HBV DNA, serum samples were first digested overnight with DNase I at 37 °C to remove the HBV plasmid pSM2, followed by extraction. The HBV DNA extracted from 100 mg liver sections at 4 dphi was subjected to Southern blotting assays. The total RNAs extracted from the liver sections at 4 dphi were subjected to a qRT-PCR assay to assess the levels of HBV pgRNA and HBV total RNAs. The primers used are listed in Supplementary Table 1.

The HBV RNAs were also detected by northern blotting. The total RNAs extracted from the liver sections at 4 dphi was subjected to Southern blotting assays. The total RNAs extracted from the liver sections at 4 dphi were subjected to a qRT-PCR assay to assess the levels of HBV pgRNA and HBV total RNAs. The primers used are listed in Supplementary Table 1. The HBV RNAs were also detected by northern blotting assay. Intrahepatic core protein were analyzed by immunohistochemical staining as described previously.

Statistical analysis

Statistical analysis was carried out using GraphPad Prism 5.0 software (GraphPad Software). The results are presented as the mean ± standard deviations (n ≥ 3). The statistical significance of the differences in multiple comparisons was determined using Student’s t-test.

For further details regarding the methods used, please refer to the supplementary materials and methods.

Data availability

The authors declare that all relevant data are available from the corresponding author upon request.

Acknowledgements

We thank the staff at the Animal Center and the Core Facility and Technical Support of Wuhan Institute of Virology for their excellent technical assistance. This work was supported by grants from the National Basic Research Priorities Program of China (2013CB911100) and the National Nature Science Foundation of China (81601760). C.W. is supported by the Youth Innovation Foundation of China (81601760). X.C. Contributed reagents/material/analysis tools: X.H., Y.Z., and H.Z. Wrote the manuscript: K.Z., C.W., and X.C.

Author contributions

Conceived and designed experiments: K.Z., C.W., and X.C. Performed the experiments: K.Z., SL, YC, YY, MZ, and YY. Analyzed the data: K.Z., C.W., YY, RP, JC, ML, and XC. Contributed reagents/material/analysis tools: XH, YZ, and HZ. Wrote the manuscript: K.Z., C.W., and XC.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at (https://doi.org/10.1038/s41426-018-0189-8).

Received: 4 July 2018 Revised: 30 September 2018 Accepted: 26 October 2018
Published online: 21 November 2018

References

1. Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212–2219 (2012).
2. Ren, X. et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J. Viral Hepat. 17, 887–895 (2010).
3. Petersen, J., Thompson, A. J. & Leverero, M. Aiming for cure in HBV and HDV infection. J. Hepatol. 65, 835–848 (2016).
4. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus: e-life 1, e00049 (2012).
5. Urban, S., Bartsch, M., Kästner, M., Scholz, S., Scholz, S. & Zoulim, F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147, 48–64 (2014).
6. Schulze, A., Scheick, M., Na, N., Yang, Y., Wier, M. & Urban, S. F. Map of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J. Virol. 84, 1989–2000 (2010).
7. Lutgehetmann, M. et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55, 685–694 (2012).
8. Volz, T. et al. The entry inhibitor myxudex-8 efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J. Hepatol. 58, 861–867 (2013).
9. Blank, A. et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myxudex-8. J. Hepatol. 65, 483–489 (2016).
10. Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myxudex-8: Results of a phase Ib/IIa study. J. Hepatol. 65, 490–498 (2016).
11. Anwer, M. S. & Steiger, B. Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflug. Arch. 466, 77–89 (2014).
12. Tautner, M. et al. Targeting nuclear bile acid receptors for liver disease. Dig. Dis. Sci. 29, 98–102 (2011).
13. Ramire, C. et al. Transactivation of the hepatitis B virus core promoter by the nuclear receptor FXR. J. Virol. 82, 10832–10840 (2008).
14. Li, J. et al. Unusual features of sodium taurocholate cotransporting polypeptide as a hepatitis B virus receptor. J. Virol. 90, 8302–8313 (2016).
15. Yan, H. et al. Viral entry of hepatitis B and D viruses and bile salts transport and share common molecular determinants on sodium taurocholate cotransporting polypeptide. J. Virol. 88, 3273–3284 (2014).
16. Li, W. H. & Urban, S. Entry of hepatitis B and hepatitis D virus into hepatocytes: basic insights and clinical implications. J. Hepatol. 64, 532–540 (2016).
17. Konig, A. et al. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J. Hepatol. 61, 867–875 (2014).
18. Zhong, G. et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J. Virol. 87, 7176–7184 (2013).
19. Yan, H. et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J. Virol. 87, 7977–7991 (2013).
20. Huang, L. R., Wu, H. L., Chen, P. J. & Chen, D. S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl Acad. Sci. USA 103, 17862–17867 (2006).
21. Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365–1368 (1999).
22. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 (1999).
23. Wagner, M., Zollner, G. & Trauner, M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver. Dis. 30, 160–177 (2010).
24. Ren, J. H. et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J. Virol. 88, 2442–2451 (2014).
25. Quasdorff, M. & Protzer, U. Control of hepatitis B virus at the level of transcription. J. Viral Hepat. 17, 527–536 (2010).
26. Lempp, F. A. & Urban, S. Hepatitis delta virus: replication strategy and upcoming therapeutic options for a neglected human pathogen. Viruses 9, pii: E172 (2017).
27. Radeloff, D. et al. Male suicide rates in German prisons and the role of citizenship. PLoS ONE 12, e0178959 (2017).
28. Kemper, J. K. et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell. Metab. 10, 392–404 (2009).
29. Deng, J. J. et al. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription. Biochim Biophys. Acta Gene Regul. Mech. 1860, 491–501 (2017).
30. Curti, C. et al. The metabolic sensors FXRalpha, PGC-1alpha, and SRT1 cooperatively regulate hepatitis B virus transcription. FASEB J. 28, 1454–1463 (2014).
31. Van Dyke, R. W., Stephens, J. E. & Schanschmidt, B. F. Bile acid transport in cultured rat hepatocytes. Am. J. Physiol. 243, G484–G492 (1982).
32. Mita, S. et al. Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G550–G556 (2006).
33. Gripon, P., Cannie, I. & Urban, S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J. Virol. 79, 1613–1622 (2005).
34. Haag, M. et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)–taurocholate cotransporting polypeptide inhibitor. Anal. Bioanal. Chem. 407, 6815–6825 (2015).
35. Zhou, M. et al. Revival, characterization, and hepatitis B virus infection of cryopreserved human fetal hepatocytes. J. Virol. Methods 207, 29–37 (2014).
36. Zhao, K. et al. Ceruloplasmin inhibits the production of extracellular hepatitis B virus by targeting its middle surface protein. J. Gen. Virol. 98, 1410–1421 (2017).
37. Zhou, M. et al. Productive HBV infection of well-differentiated, hNTCP-expressing human hepatoma-derived (Huh7) cells. Virol. Sin. 32, 465–475 (2017).
38. Gao, L. et al. Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses. J. Virol. 88, 8656–8666 (2014).
39. Liu, S. et al. MITA/STING and its alternative splicing isoform MRP restrict hepatitis B virus replication. PLoS ONE 12, e0169701 (2017).